Breaking News, Collaborations & Alliances

Regeneron, Sonoma Biotherapeutics Partner on Treg Cell Therapies

Alliance brings together Regeneron’s VelociSuite with Sonoma’s approach to developing and manufacturing gene modified Treg cell therapies.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Regeneron Pharmaceuticals, Inc. and Sonoma BioTherapeutics Inc. entered a collaboration to apply their scientific and clinical expertise and respective technology platforms to the discovery, development and commercialization of novel regulatory T cell (Treg) therapies for autoimmune diseases. The collaboration leverages Regeneron’s VelociSuite technologies for the discovery and characterization of fully human antibodies and T cell receptors (TCRs) with Sonoma Biotherapeutics’ pioneering appro...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters